Get the Stockscreener App
5.82
1.93%
0.11
After Hours:
5.83
0.010
+0.17%
Forte Biosciences Inc Stock (FBRX) Latest News
Forte Biosciences (FBRX) Expected to Announce Quarterly Earnings on Monday - Defense World
Traders Purchase High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Update - MarketBeat
Forte Biosciences Stock Down 20% But Insiders Still In US$92k Profit - Simply Wall St
Pre-market Movers: ISPC, TH, IVVD, TOVX... - RTTNews
(FBRX) On The My Stocks Page - Stock Traders Daily
Stock Traders Buy Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - MarketBeat
Evelo Biosciences Target of Unusually Large Options Trading (NASDAQ:EVLO) - Defense World
One Forte Biosciences Insider Raised Stake By 273% In Previous Year - Yahoo Finance
Best Stocks Under $20 Right Now - Benzinga
Where are the Opportunities in (FBRX) - Stock Traders Daily
Stock Traders Buy High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - MarketBeat
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings -February 03, 2025 at 09:03 am EST - Marketscreener.com
Autoimmune Biotech Forte Lines Up Strategic Presentations at Major Healthcare Investment Forums - StockTitan
(FBRX) Proactive Strategies - Stock Traders Daily
CSG Forte Wins TSG Real Transaction Metrics Awards for Second Consecutive Year - Yahoo Finance
Forte Biosciences expands equity incentive plan By Investing.com - Investing.com Australia
TD Cowen initiates Forte Biosciences stock with Buy rating - MSN
Forte Biosciences expands equity incentive plan - MSN
Traders Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
Meiwu Technology (NYSE:WNW) Stock Price Down 13.2% – Here’s Why - Defense World
Forte Biosciences (NASDAQ:FBRX) Coverage Initiated by Analysts at TD Cowen - Defense World
TD Cowen initiates Forte Biosciences stock with Buy rating By Investing.com - Investing.com Australia
Atopic Dermatitis Drugs Market Trends Analysis Report - GlobeNewswire
(FBRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX) - Defense World
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
(FBRX) Technical Data - Stock Traders Daily
Investors Purchase Large Volume of Put Options on Evelo Biosciences (NASDAQ:EVLO) - Defense World
Investors Buy High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
(FBRX) Long Term Investment Analysis - Stock Traders Daily
100 cell and gene therapy leaders to watch in 2025 - Drug Discovery & Development
Why Forte Biosciences (FBRX) Stock Is Trading Lower - Benzinga
CBD Life Sciences Inc. (OTCMKTS:CBDL) Short Interest Up 8,233.3% in November - Defense World
Traders Buy Large Volume of Call Options on Quantum-Si (NASDAQ:QSI) - Defense World
Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors - The Manila Times
Trading (FBRX) With Integrated Risk Controls - Stock Traders Daily
FBRX Stock Soars to 52-Week High, Reaching $24.46 By Investing.com - Investing.com Nigeria
FBRX Stock Soars to 52-Week High, Reaching $24.46 - Investing.com
Forte Biosciences’ $53 Million Equity Financing - Global Legal Chronicle
Biopharma Takes on Deadly Brain Cancer After Decades of Failure - BioSpace
(FBRX) Trading Report - Stock Traders Daily
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going - MSN
FBRX Stock Soars to 52-Week High, Reaching $21.47 - Investing.com India
FBRX Stock Soars to 52-Week High, Reaching $21.47 By Investing.com - Investing.com UK
Forte Biosciences Sets R&D Day to Showcase FB102 Autoimmune Treatment Pipeline | FBRX Stock News - StockTitan
Forte Biosciences CFO acquires $124,997 in company stock By Investing.com - Investing.com Canada
Forte Biosciences CFO acquires $124,997 in company stock - Investing.com
More than $50M raised by publicly traded drug developer - The Business Journals
Dallas' Forte Biosciences Announces $53M Private Placement From Leading Healthcare Investors - dallasinnovates.com
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):